Arcutis Biotherapeutics, Inc. (ARQT): Long-Term Debt
$108.96M
As of 2025-12-31
$108.90M
As of 2026-06-30
-18.0%
3-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $108.96M | +1.6% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $107.20M | -46.9% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $201.80M | +2.0% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $197.77M | +173.4% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $72.35M | n/a | 2023-02-28, Balance as of period end |
| 2020-12-31 | $0 | n/a | 2022-02-22, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $108.96M | +1.6% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $494.86M | +31.7% |
| MannKind Corp (MNKD) | 2025-12-31 | $354.64M | +883.7% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $202.83M | +34.5% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $146.10M | +20.2% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $220.34M | -5.1% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $2.01B | n/a |
| Harrow, Inc. (HROW) | 2025-12-31 | $250.00M | -4.8% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $600.0K | -25.0% |
Compare ARQT, SVA, MNKD, ARDX side by side · Screen every company in Pharmaceutical Preparations ↗